Portal de Periódicos da CAPES

COVID‐SAFER : Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults

2020; Wiley; Volume: 68; Issue: 8 Linguagem: Inglês

10.1111/jgs.16623

1532-5415

Sydney B. Ross, Marnie Goodwin Wilson, Louise Papillon‐Ferland, S Elsayed, Peter E. Wu, Kiran Battu, Sandra Porter, Babak Rashidi, Robyn Tamblyn, Louise Pilote, James Downar, André Bonnici, Allen Huang, Todd C. Lee, Emily G. McDonald,

Pharmacovigilance and Adverse Drug Reactions

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug-drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine.